Evidence map›Paper›PMID 17555564›Full record

ArticleBMC health services research2007

Healthcare utilization of patients accessing an African national treatment program.

Guy Harling, Catherine Orrell, Robin Wood

Abstract read
In one paragraph

Article in BMC health services research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. The impact of HIV-associated anaemia on the incidence of red blood cell transfusion: implications for blood services in HIV-endemic countries.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2014
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Treatment of cryptococcal meningitis in resource limited settings.Current opinion in infectious diseases · 2009
    Review
  12. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2009
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Guy HarlingThe Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, South Africa. Guy.Harling@gmail.com
Catherine Orrell
Robin Wood

Funding

The effect of ART on rates and transmission of TBU19AI053217 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI MCINTYRE, JAMES ALASDAIR · 2002 to 2011
$44.9M
Optimizing HIV Care in Less Developed CountriesR01AI058736 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Kenneth Alan Freedberg, Emily Parker Hyle · 2004 to 2026
$21.5M
NIAID NIH HHS 1U19AI53217-01NIAID NIH HHS R01 AI058736NIAID NIH HHS R01AI058736-01A1NIAID NIH HHS U19 AI053217
6 · The paper itself

Abstract

backgroundThe roll-out of antiretroviral therapy (ART) in Africa will have significant resource implications arising from its impact on demand for healthcare services. Existing studies of healthcare utilization on HAART have been conducted in the developed world, where HAART is commenced when HIV illness is less advanced.

methodsThis paper describes healthcare utilization from program entry by treatment-naïve patients in a peri-urban settlement in South Africa. Treatment criteria included a CD4 cell count <200 cells/microl or an AIDS-defining illness. Data on health service utilization were collected retrospectively from the primary-care clinic and secondary and tertiary referral hospitals. Hospital visits were reviewed to determine the clinical reason for each visit.

results212 patients were followed for a median of 490 days. Outpatient visits per 100 patient years of observation (PYO), excluding scheduled primary-care follow-up, fell from 596 immediately prior to ART to 334 in the first 48 weeks on therapy and 245 thereafter. Total inpatient time fell from 2,549 days per 100 PYO pre-ART to 476 in the first 48 weeks on therapy and 73 thereafter. This fall in healthcare utilization occurred at every level of care. The greatest causes of utilization were tuberculosis, cryptococcal meningitis, HIV-related neoplasms and adverse reactions to stavudine. After 48 weeks on ART demand reverted to primarily non-HIV-related causes.

conclusionUtilization of both inpatient and outpatient hospital services fell significantly after commencement of ART for South African patients in the public sector, with inpatient demand falling fastest. Earlier initiation might reduce early on-ART utilization rates.

Indexed as

Acquired Immunodeficiency SyndromeAdultAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountCommunity Health CentersFemaleHealth Knowledge, Attitudes, PracticeHealth Services Needs and DemandHIV InfectionsHumansMaleNational Health ProgramsOutpatient Clinics, HospitalRetrospective StudiesSouth AfricaAnti-Retroviral Agents

Identifiers

PMID17555564
PMCPMC1899174

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.